Volume 15, Issue 1 ( March 2023 2023)                   Iranian Journal of Blood and Cancer 2023, 15(1): 71-79 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Saki N, Javan M, Shokouhian M, Bagheri M, Moghimian-boroujeni B. A review of the interaction between the coagulation system and cancer. Iranian Journal of Blood and Cancer 2023; 15 (1) :71-79
URL: http://ijbc.ir/article-1-1375-en.html
A review of the interaction between the coagulation system and cancer
Najmaldin Saki1 , Mohammadreza Javan2 , Mohammad Shokouhian3 , Marzieh Bagheri1 , Bahareh Moghimian-boroujeni * 4
1- Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Iranian Blood Transfusion Organization (IBTO), Tehran, Iran
3- Department of Hematology and Blood Transfusion, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
4- Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran , bahar.moghimian.74@gmail.com
Abstract:   (723 Views)

Background: Interaction between cancer cells and the coagulation system could have reciprocal effects on both groups. Coagulation-fibrinolytic cascade is a process that regulates the homeostasis of the body, and this process can be disrupted by several factors; one of the most important factor is cancer. In contrast, the coagulation-fibrinolytic system can also act as a factor in cancer growth and metastasis. Our aim in this study is to investigate this relationship.
Methods: The present study is based on Pubmed database information (2010- 2023) using the words “Cancer”, “Coagulation”, “Platelet “, “Tissue factor” and “ VTE “.
Results: Cancer cells disrupt the coagulation process by activating prooncogenic factors or inhibiting tumor suppressors, thereby inducing changes in platelets and coagulation factors, and increasing proteins involved in coagulation. These aberrations in the coagulation system result in coagulation abnormalities such as venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC). In various cancers, the activity of the coagulation and fibrinolytic systems increases, leading to an increase in coagulation and fibrinolysis factors. These factors are closely related to tumor size, tumor stage, cancer progression and metastasis.
Conclusions: The coagulation-fibrinolytic system is closely related to cancers.Cancer cells can disrupt the coagulation-fibrinolysis process. Also, coagulation-fibrinolytic agents can both lead to cancer progression and can be used as a marker for the prognosis of some cancers.

Keywords: Cancer, Coagulation, Venous thromboembolism, Platelet, Tissue factor
Full-Text [PDF 863 kb]   (353 Downloads)    
Subject: Adults Hematology & Oncology
Received: 2023/01/26 | Accepted: 2023/03/17 | Published: 2023/03/30
References
1. Seki Y, Wakaki K. Pathological findings in a case of bone marrow carcinosis due to gastric cancer complicated by disseminated intravascular coagulation and thrombotic microangiopathy. International journal of hematology. 2016;104(4):506-11. [DOI:10.1007/s12185-016-2051-x]
2. Han X, Zha H, Yang F, Guo B, Zhu B. Tumor-derived tissue factor aberrantly activates complement and facilitates lung tumor progression via recruitment of myeloid-derived suppressor cells. International journal of molecular sciences. 2017;18(1):22. [DOI:10.3390/ijms18010022]
3. Leppert U, Eisenreich A. The role of tissue factor isoforms in cancer biology. International journal of cancer. 2015;137(3):497-503. [DOI:10.1002/ijc.28959]
4. Ishihara T, Nogami K, Takeshita Y, Ochi S, Shima M. Fibrinolytic abnormality associated with progression of pediatric solid tumor. Pediatrics International. 2018. [DOI:10.1111/ped.13546]
5. Sallah S, Wan JY, Nguyen NP, Hanrahan L, Sigounas G. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thrombosis and haemostasis. 2001;85(03):828-33. [DOI:10.1055/s-0037-1616139]
6. Mego M, Karaba M, Minarik G, Benca J, Sedlácková T, Tothova L, et al. Relationship between circulating tumor cells, blood coagulation, and urokinase‐plasminogen‐activator system in early breast cancer patients. The breast journal. 2015;21(2):155-60. [DOI:10.1111/tbj.12388]
7. Wakatsuki K, Matsumoto S, Migita K, Kunishige T, Nakade H, Miyao S, et al. Prognostic value of the fibrinogen-to-platelet ratio as an inflammatory and coagulative index in patients with gastric cancer. Surgery today. 2019;49(4):334-42. [DOI:10.1007/s00595-018-1734-8]
8. Nickel KF, Labberton L, Long AT, Langer F, Fuchs TA, Stavrou EX, et al. The polyphosphate/factor XII pathway in cancer-associated thrombosis: novel perspectives for safe anticoagulation in patients with malignancies. Thrombosis research. 2016;141:S4-S7. [DOI:10.1016/S0049-3848(16)30353-X]
9. Kim S-H, Lee HW, Go S-I, Lee SI, Lee G-W. Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer. Oncotarget. 2016;7(24):36198. [DOI:10.18632/oncotarget.8809]
10. Omar M, Tanriverdi O, Cokmert S, Oktay E, Yersal O, Pilancı KN, et al. Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer. The clinical respiratory journal. 2018;12(3):922-9. [DOI:10.1111/crj.12605]
11. Yuan L, Liu X. Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism. Molecular medicine reports. 2015;11(4):2449-58. [DOI:10.3892/mmr.2014.3082]
12. Suega K, Bakta IM. Correlation between clinical stage of solid tumor and D dimer as a marker of coagulation activation. Acta Med Indones. 2011;43(3):162-7.
13. Guo X, Zhang F, Wu Y, Gao L, Wang Q, Wang Z, et al. Coagulation alteration and deep vein thrombosis in brain tumor patients during the perioperative period. World neurosurgery. 2018;114:e982-e91. [DOI:10.1016/j.wneu.2018.03.128]
14. Saadeh FA, Langhe R, Galvin D, Toole SO, O'Donnell D, Gleeson N, et al. Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy. Thrombosis research. 2016;139:135-41. [DOI:10.1016/j.thromres.2016.01.027]
15. Mi X, Liu Q, Zhu L, Sang M, Guo L, Shan B. Mechanism of the high coagulation state of breast cancer tissue factor. Eur Rev Med Pharmacol Sci. 2017;21(9):2167-71.
16. Das K, Prasad R, Ansari SA, Roy A, Mukherjee A, Sen P. Matrix metalloproteinase-2: A key regulator in coagulation proteases mediated human breast cancer progression through autocrine signaling. Biomedicine & pharmacotherapy. 2018;105:395-406. [DOI:10.1016/j.biopha.2018.05.155]
17. Topcu TO, Kavgaci H, Ozdemir F, Aksoy A, Erdem D, Mentese A, et al. Elevated serum levels of SCUBE1, a marker for coagulation, in patients with breast cancer. The Tohoku journal of experimental medicine. 2015;237(2):127-32. [DOI:10.1620/tjem.237.127]
18. Kilic L, Yildiz I, Sen FK, Erdem MG, Serilmez M, Keskin S, et al. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients. Cancer Biomarkers. 2015;15(4):405-11. [DOI:10.3233/CBM-150477]
19. Tinholt M, Viken MK, Dahm AE, Vollan HKM, Sahlberg KK, Garred Ø, et al. Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study. Bmc Cancer. 2014;14(1):1-11. [DOI:10.1186/1471-2407-14-845]
20. van der Spuy WJ, Augustine TN. Ultrastructural investigation of the time-dependent relationship between breast cancer cells and thrombosis induction. Micron. 2016;90:59-63. [DOI:10.1016/j.micron.2016.08.006]
21. Rousseau A, Van Dreden P, Khaterchi A, Larsen AK, Elalamy I, Gerotziafas GT. Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer. International journal of oncology. 2017;51(6):1793-800. [DOI:10.3892/ijo.2017.4170]
22. Ruf W, Schaffner F. Role of the protein C receptor in cancer progression. Thrombosis research. 2014;133:S85-S9. [DOI:10.1016/S0049-3848(14)50014-X]
23. Pang M, Zhao F, Yu P, Zhang X, Xiao H, Qiang W, et al. The significance of coagulation and fibrinolysis-related parameters in predicting postoperative venous thrombosis in patients with breast cancer. Gland Surgery. 2021;10(4):1439. [DOI:10.21037/gs-21-117]
24. Eisenreich A, Zakrzewicz A, Huber K, Thierbach H, Pepke W, Goldin-Lang P, et al. Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells. Oncology reports. 2013;30(1):462-70. [DOI:10.3892/or.2013.2413]
25. Eisenreich A, Boltzen U, Malz R, Schultheiss H-P, Rauch U. Overexpression of alternatively spliced tissue factor induces the pro-angiogenic properties of murine cardiomyocytic HL-1 cells. Circulation Journal. 2011;75(5):1235-42. [DOI:10.1253/circj.CJ-10-0783]
26. Grafetstätter M, Hüsing A, Maldonado SG, Sookthai D, Johnson T, Pletsch-Borba L, et al. Plasma fibrinogen and sP-selectin are associated with the risk of lung cancer in a prospective study. Cancer Epidemiology and Prevention Biomarkers. 2019;28(7):1221-7. [DOI:10.1158/1055-9965.EPI-18-1285]
27. Ma R, Bi Y, Kou J, Zhou J, Shi J. Enhanced procoagulant activity of platelets after chemotherapy in non-small cell lung cancer. Cancer biology & therapy. 2017;18(8):627-34. [DOI:10.1080/15384047.2017.1345387]
28. Zer A, Moskovitz M, Hwang DM, Hershko-Klement A, Fridel L, Korpanty GJ, et al. ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. Clinical lung cancer. 2017;18(2):156-61. [DOI:10.1016/j.cllc.2016.10.007]
29. Li R, Hermann G, Baldini E, Chen A, Jackman D, Kozono D, et al. Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer. Lung Cancer. 2016;96:41-7. [DOI:10.1016/j.lungcan.2016.03.004]
30. Koldas M, Gumus M, Seker M, Seval H, Karaoglu H, Dane F, et al. Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer. Clinical lung cancer. 2008;9(2):112-5. [DOI:10.3816/CLC.2008.n.017]
31. Masago K, Fujita S, Mio T, Togashi Y, Kim YH, Hatachi Y, et al. Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer. Medical Oncology. 2011;28(1):351-6. [DOI:10.1007/s12032-010-9454-y]
32. Zhu M, Dai Y, Gao F, Xu C, Chen L, Xu Y, et al. Correlations of coagulation indexes and inflammatory changes with the prognosis of lung cancer complicated with thromboembolic disease. J BUON. 2019;24:585-90.
33. Davies N, Harrison N, Sabra A, Lawrence M, Noble S, Davidson S, et al. Application of ROTEM to assess hypercoagulability in patients with lung cancer. Thrombosis research. 2015;135(6):1075-80. [DOI:10.1016/j.thromres.2015.03.021]
34. Ke L, Cui S, Chen S, Hu B, Li H. Dynamics of D‐dimer in non‐small cell lung cancer patients receiving radical surgery and its association with postoperative venous thromboembolism. Thoracic cancer. 2020;11(9):2483-92. [DOI:10.1111/1759-7714.13559]
35. Guo X, Zhang F, Wu Y, Gao L, Wang Q, Wang Z, et al. Coagulation Alteration and Deep Vein Thrombosis in Brain Tumor Patients During the Perioperative Period. (1878-8769 (Electronic)).
36. Nielsen VG, Lemole Jr GM, Matika RW, Weinand ME, Hussaini S, Baaj AA, et al. Brain tumors enhance plasmatic coagulation: the role of hemeoxygenase-1. Anesthesia & Analgesia. 2014;118(5):919-24. [DOI:10.1213/ANE.0000000000000048]
37. Zwicker J, Karp Leaf R, Carrier M. A meta‐analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. Journal of Thrombosis and Haemostasis. 2016;14(9):1736-40. [DOI:10.1111/jth.13387]
38. Navone SE, Guarnaccia L, Locatelli M, Rampini P, Caroli M, La Verde N, et al. Significance and prognostic value of the coagulation profile in patients with glioblastoma: implications for personalized therapy. World neurosurgery. 2019;121:e621-e9. [DOI:10.1016/j.wneu.2018.09.177]
39. Yang C, Ma R, Jiang T, Cao M, Zhao L, Bi Y, et al. Contributions of phosphatidylserine-positive platelets and leukocytes and microparticles to hypercoagulable state in gastric cancer patients. Tumor Biology. 2016;37(6):7881-91. [DOI:10.1007/s13277-015-4667-5]
40. Yang C, Sun W, Cui W, Li X, Yao J, Jia X, et al. Procoagulant role of neutrophil extracellular traps in patients with gastric cancer. International journal of clinical and experimental pathology. 2015;8(11):14075.
41. Hara K, Aoyama T, Hayashi T, Nakazono M, Nagasawa S, Shimoda Y, et al. Postoperative D-dimer elevation affects tumor recurrence and the long-term survival in gastric cancer patients who undergo gastrectomy. International journal of clinical oncology. 2020;25(4):584-94. [DOI:10.1007/s10147-019-01603-x]
42. Zhang L, Wang Z, Xiao J, Zhang Z, Li H, Wang Y, et al. Prognostic value of fibrinogen‑to‑albumin ratio in patients with gastric cancer receiving first‑line chemotherapy. Oncology Letters. 2020;20(4):1-. https://doi.org/10.3892/ol.2020.12255 https://doi.org/10.3892/ol.2020.12114 https://doi.org/10.3892/ol.2020.12132 https://doi.org/10.3892/ol.2020.12158 https://doi.org/10.3892/ol.2020.12116 https://doi.org/10.3892/ol.2020.12180 https://doi.org/10.3892/ol.2020.11953 https://doi.org/10.3892/ol.2020.12153 https://doi.org/10.3892/ol.2020.12174 https://doi.org/10.3892/ol.2020.12304 https://doi.org/10.3892/ol.2020.12101 https://doi.org/10.3892/ol.2020.12300 [DOI:10.3892/ol.2020.12168]
43. Mitrugno A, Tassi Yunga S, Sylman JL, Zilberman-Rudenko J, Shirai T, Hebert JF, et al. The role of coagulation and platelets in colon cancer-associated thrombosis. American Journal of Physiology-Cell Physiology. 2019;316(2):C264-C73. [DOI:10.1152/ajpcell.00367.2018]
44. Wojtukiewicz MZ, Mysliwiec M, Sierko E, Sobierska M, Kruszewska J, Lipska A, et al. Elevated microparticles, thrombin-antithrombin and VEGF levels in colorectal cancer patients undergoing chemotherapy. Pathology & Oncology Research. 2020;26(4):2499-507. [DOI:10.1007/s12253-020-00854-8]
45. Moik F, Posch F, Grilz E, Scheithauer W, Pabinger I, Prager G, et al. Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer. Thrombosis research. 2020;187:9-17. [DOI:10.1016/j.thromres.2020.01.002]
46. Zhang L, Ye J, Luo Q, Kuang M, Mao M, Dai S, et al. Prediction of Poor Outcomes in Patients with Colorectal Cancer: Elevated Preoperative Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT). Cancer management and research. 2020;12:5373. [DOI:10.2147/CMAR.S246695]
47. Copija A, Nowakowska-Zajdel E, Janion K, Walkiewicz K. Clinical characteristics of colorectal cancer patients in terms of selected platelet indices. Disease Markers. 2020;2020. [DOI:10.1155/2020/6145604]
48. Yuan L, Liu X. Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism. (1791-3004 (Electronic)).
49. Wang J, Zhu M, Zhou X, Wang T, Zhang J. Changes in tumor markers, coagulation function and serum VEGF in patients with ovarian cancer and benign ovarian. 2020.
50. Yang J, Jin Y, Cheng S, Wang C, Zhang N, Huang S, et al. Clinical significance for combined coagulation indexes in epithelial ovarian cancer prognosis. Journal of Ovarian Research. 2021;14(1):1-10. [DOI:10.1186/s13048-021-00858-1]
51. Yang J, Ma J, Cheng S, Wang Y. The Combination of Plasma Fibrinogen Concentration and Neutrophil Lymphocyte Ratio (F-NLR) as a Prognostic Factor of Epithelial Ovarian Cancer. OncoTargets and therapy. 2020;13:7283. [DOI:10.2147/OTT.S264118]
52. Zhang W, Peng P, Ou X, Shen K, Wu X. Ovarian cancer circulating extracelluar vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis. BMC cancer. 2019;19(1):1-13. https://doi.org/10.1186/s12885-019-6176-1 [DOI:10.1158/1538-7445.AM2019-1]
53. Zhang W, Ou X, Wu X. Proteomics profiling of plasma exosomes in epithelial ovarian cancer: A potential role in the coagulation cascade, diagnosis and prognosis. International journal of oncology. 2019;54(5):1719-33. [DOI:10.3892/ijo.2019.4742]
54. Unruh D, Turner K, Srinivasan R, Kocatürk B, Qi X, Chu Z, et al. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. International journal of cancer. 2014;134(1):9-20. [DOI:10.1002/ijc.28327]
55. Nielsen VG, Nfonsam VN, Matika RW, Ong ES, Jie T, Warneke JA, et al. Colon and pancreas tumors enhance coagulation: role of hemeoxygenase-1. Blood Coagulation & Fibrinolysis. 2014;25(5):435-8. [DOI:10.1097/MBC.0000000000000075]
56. Ruiz-Sada P, Nahia A-U, Iker G-H, Katalin U-E. Primary hyperfibrinolysis as a presentation of extended prostate carcinoma. Rom J Intern Med. 2016;54(3):191-3. [DOI:10.1515/rjim-2016-0017]
57. Kulić A, Cvetković Z, Libek V. Primary hyperfibrinolysis as the presenting sign of prostate cancer: a case report. Vojnosanitetski pregled. 2016;73(9):877-80. [DOI:10.2298/VSP150525076K]
58. Li S, Di Zhang SZ, Wu T, Wang Y, Zhang H, Wang B, et al. Prognostic Value of Preoperative Albumin-to-Fibrinogen Ratio in Patients with Bladder Cancer. Journal of Cancer. 2021;12(19):5864. https://doi.org/10.7150/jca.61068 [DOI:10.7150/jca.61866]
59. Li X, Shu K, Zhou J, Yu Q, Cui S, Liu J, et al. Preoperative plasma fibrinogen and D-dimer as prognostic biomarkers for non-muscle-invasive bladder cancer. Clinical genitourinary cancer. 2020;18(1):11-9. e1. [DOI:10.1016/j.clgc.2019.10.025]
60. Luo Y-L, Chi P-D, Zheng X, Zhang L, Wang X-P, Chen H. Preoperative D-dimers as an independent prognostic marker in cervical carcinoma. Tumor Biology. 2015;36(11):8903-11. [DOI:10.1007/s13277-015-3650-5]
61. Jing W, Peng R, Zhu M, Lv S, Jiang S, Ma J, et al. Differential expression and diagnostic significance of pre-albumin, fibrinogen combined with D-dimer in AFP-negative hepatocellular carcinoma. Pathology & Oncology Research. 2020;26(3):1669-76. [DOI:10.1007/s12253-019-00752-8]
62. Mi X, Liu Q, Zhu L, Sang M, Guo L, Shan B. Mechanism of the high coagulation state of breast cancer tissue factor. Eur Rev Med Pharmacol Sci. 2017;21(9):2167-71.
63. Yang C, Sun W, Cui W, Li X, Yao J, Jia X, et al. Procoagulant role of neutrophil extracellular traps in patients with gastric cancer. (1936-2625 (Electronic)).
64. Kulic A Fau - Cvetkovic Z, Cvetkovic Z Fau - Libek V, Libek V. Primary hyperfibrinolysis as the presenting sign of prostate cancer: A case report. (0042-8450 (Print)).
65. Graf C, Ruf W. Tissue factor as a mediator of coagulation and signaling in cancer and chronic inflammation. Thrombosis research. 2018;164:S143-S7. [DOI:10.1016/j.thromres.2018.01.023]
66. Nadir Y, Brenner B. Novel strategies of coagulation inhibition for reducing tumor growth and angiogenesis. Thrombosis Research. 2018;164:S153-S6. [DOI:10.1016/j.thromres.2017.12.011]
67. Vassalo J, Spector N, de Meis E, Rabello LS, Rosolem MM, do Brasil PE, et al. Antiphospholipid antibodies in critically ill patients with cancer: a prospective cohort study. Journal of critical care. 2014;29(4):533-8. [DOI:10.1016/j.jcrc.2014.02.005]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb